Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Understand when bonds add stability to a retirement portfolio and how they complement stocks to protect income during drawdown periods.
22,007 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Greg Abel delivers his first annual letter as Berkshire’s CEO, outlining continuity after a $4.5 billion write-down o...
Analysts lean bullish on Apollo Global Management after a flurry of dealmaking, with elevated price targets and visib...
Onity wins approval revised terms for a major reverse mortgage MSR sale to FOA, narrowing the portfolio and shifting ...
In a volatile rate environment, DIVO remains a focal point for income investors. This report analyzes payout stabilit...
A $7.6 billion ETF focused on smart grid infrastructure charges a 0.56% fee to capture AI power demand, centering on ...
CoreWeave faced a sharp move after its latest earnings, with shares slipping in after-hours trading despite a top-lin...
As AI demands surge, CoreWeave positions itself as a specialized cloud provider for GPU compute. This article digs in...
Verizon Communications stock soaring in 2026 has investors debating its next move. This guide breaks down the drivers...
Opendoor's CEO recently bought 100,000 shares, signaling confidence to shareholders. This article breaks down what t...
A tectonic shift is quietly unfolding in mobility and AI. The trillion robotaxi boom real could power a new era of ea...
On a day when markets shuddered, TJX stood out as its shares rose. A mix of solid earnings signals, a supportive anal...